Literature DB >> 22632640

Cutaneous and mucocutaneous leishmaniasis.

Hiro Goto1, José Angelo Lauletta Lindoso.   

Abstract

Tegumentary leishmaniases are caused by approximately 15 species of protozoa of the genus Leishmania. They prevail in tropical and subtropical areas of the Old and New World but human mobility also makes them a medical problem in nonendemic areas. Clinical manifestations may comprise cutaneous and mucocutaneous forms that may be localized, disseminated, or diffuse in distribution and may differ in Old and New World leishmaniases. Diagnosis and treatment vary according to the clinical manifestations, geographic area, and Leishmania species involved. This article highlights the diversity and complexity of tegumentary leishmaniases, which are worsened by human immunodeficiency virus/Leishmania coinfection.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22632640     DOI: 10.1016/j.idc.2012.03.001

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  42 in total

1.  Eligibility for Local Therapies in Adolescents and Adults with Cutaneous Leishmaniasis from Southwestern Colombia: A Cross-Sectional Study.

Authors:  Andrés Felipe Uribe-Restrepo; Miguel Dario Prieto; Alexandra Cossio; Mayur M Desai; María Del Mar Castro
Journal:  Am J Trop Med Hyg       Date:  2019-02       Impact factor: 2.345

2.  Achievement amastigotes of Leishmania infantum and investigation of pathological changes in the tissues of infected golden hamsters.

Authors:  Sajad Rashidi; Kurosh Kalantar; Gholamreza Hatam
Journal:  J Parasit Dis       Date:  2018-03-05

3.  Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective Study.

Authors:  Mirella A Cunha; Aline C Q Leão; Rita de Cassia Soler; José Angelo L Lindoso
Journal:  Am J Trop Med Hyg       Date:  2015-10-19       Impact factor: 2.345

4.  Improving the sensitivity of an hsp20-based PCR for genus detection of Leishmania parasites in cutaneous clinical samples: a proof of concept.

Authors:  Ana M Montalvo; Annia Alba; Jorge Fraga; Ana Marzoa; Cecia Torres; Carlos Muskus
Journal:  Parasitol Res       Date:  2019-11-27       Impact factor: 2.289

5.  Cutaneous Leishmaniasis: Current Treatment Practices in the USA for Returning Travelers.

Authors:  Daniel P Eiras; Laura A Kirkman; Henry W Murray
Journal:  Curr Treat Options Infect Dis       Date:  2015-03-01

6.  Dermatoscopic signs in cutaneous leishmaniasis.

Authors:  María Librada Porriño Bustamante; Josefa Sánchez López; Carmen Dulanto Campos; Ramón Naranjo Sintes; María Antonia Fernández Pugnaire
Journal:  An Bras Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.896

7.  Analytical Performance of a Loop-Mediated Isothermal Amplification Assay for Leishmania DNA Detection in Sandflies and Direct Smears of Patients with Cutaneous Leishmaniasis.

Authors:  Cielo M León; Marina Muñoz; Juan H Tabares; Carolina Hernandez; Carolina Florez; Martha S Ayala; Juan David Ramírez
Journal:  Am J Trop Med Hyg       Date:  2018-03-08       Impact factor: 2.345

Review 8.  Leishmaniasis: clinical syndromes and treatment.

Authors:  B S McGwire; A R Satoskar
Journal:  QJM       Date:  2013-06-05

9.  Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis.

Authors:  Anny Fortin; Diana P Caridha; Susan Leed; Franklyn Ngundam; Jenell Sena; Tom Bosschaerts; Sandi Parriott; Mark R Hickman; Thomas H Hudson; Max Grogl
Journal:  PLoS Negl Trop Dis       Date:  2014-09-11

10.  Potent In Vitro Antiproliferative Synergism of Combinations of Ergosterol Biosynthesis Inhibitors against Leishmania amazonensis.

Authors:  S T de Macedo-Silva; G Visbal; J A Urbina; W de Souza; J C F Rodrigues
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.